ReviewRadiology and oncology2016
Malignant gliomas: old and new systemic treatment approaches.
Review in Radiology and oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Understanding Neovascularization in Glioblastoma: Insights from the Current Literature.International journal of molecular sciences · 2025Review
- Optimizing Glioblastoma, IDH-wildtype Treatment Outcomes : A Radiomics and Support Vector Machine-Based Approach to Overall Survival Estimation.Journal of Korean Neurosurgical Society · 2025Article
- Pivotal Role of Cranial Irradiation-Induced Peripheral, Intrinsic, and Brain-Engrafting Macrophages in Malignant Glioma.Clinical Medicine Insights. Oncology · 2024Review
- A Wearable Fluorescence Imaging Device for Intraoperative Identification of Human Brain Tumors.IEEE journal of translational engineering in health and medicine · 2024Article
- Article
- Blocking hsa_circ_0006168 suppresses cell proliferation and motility of human glioblastoma cells by regulating hsa_circ_0006168/miR-628-5p/IGF1R ceRNA axis.Cell cycle (Georgetown, Tex.) · 2021Article
- Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma.Ecancermedicalscience · 2021Article
- Tumor Treating Fields in the Management of Patients with Malignant Gliomas.Current treatment options in oncology · 2020Review
- Efficiency of High and StandardJournal of oncology · 2020Article
- Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme.Journal of contemporary brachytherapy · 2019Article
- CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Article
- Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.Radiology and oncology · 2018Article
- MEG-3-mediated Wnt/β-catenin signaling pathway controls the inhibition of tunicamycin-mediated viability in glioblastoma.Oncology letters · 2018Article
- Tunicamycin inhibits progression of glioma cells through downregulation of the MEG-3-regulated wnt/β-catenin signaling pathway.Oncology letters · 2018Article
- p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.Cellular oncology (Dordrecht, Netherlands) · 2018Article
- Mitochondrial energy metabolism and signalling in human glioblastoma cell lines with different PTEN gene status.Journal of bioenergetics and biomembranes · 2018Article
- Alisertib induces GAmerican journal of translational research · 2017Article
- Fluorescence-guided resection of brain tumor: review of the significance of intraoperative quantification of protoporphyrin IX fluorescence.Neurophotonics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant (high-grade) gliomas are rapidly progressive brain tumours with very high morbidity and mortality. Until recently, treatment options for patients with malignant gliomas were limited and mainly the same for all subtypes of malignant gliomas. The treatment included surgery and radiotherapy. Chemotherapy used as an adjuvant treatment or at recurrence had a marginal role.
conclusionsNowadays, the treatment of malignant gliomas requires a multidisciplinary approach. The treatment includes surgery, radiotherapy and chemotherapy. The chosen approach is more complex and individually adjusted. By that, the effect on the survival and quality of life is notable higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.